Johnson & Johnson vs Novartis

Johnson & Johnson (JNJ), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Johnson & Johnson is worth $675.9B on the stock market and Novartis $302B: Johnson & Johnson is valued at 2.2 times as much. Johnson & Johnson trades at 42.6 times earnings and Novartis at 30.5. Over the past year Johnson & Johnson's share price has moved +41.3% and Novartis's +25.1%.

Key facts

Johnson & Johnson market value
$675.9B
Novartis market value
$302B
Johnson & Johnson P/E
42.6
Novartis P/E
30.5
Johnson & Johnson revenue
$94.2BFY to 2025-12-28
Novartis revenue
$54.5BFY to 2025-12-31
Superinvestors holding both
8

Market values as of .

Johnson & Johnson vs Novartis: every measure side by side
Measure Johnson & Johnson Novartis
SectorHealth CareHealth Care
Country United States Switzerland
Fiscal year ends2025-12-282025-12-31
Size
Market cap$675.9Bhigher$302Blower
Revenue$94.2Bhigher$54.5Blower
Earnings$26.8Bhigher$14Blower
Employees138,200higher75,267lower
Total assets$199.2Bhigher$110.9Blower
Valuation
P/E42.6higher30.5lower
P/S7.2higher5.5lower
P/B8.3—
Dividend yield1.87%—
Profitability
Operating margin—32.4%
Balance sheet
Net assets$81.5Bhigher$46.1Blower
Total liabilities$117.7Bhigher$64.4Blower
Total debt$47.9Bhigher$28.7Blower
Cash on hand$19.7Bhigher$11.4Blower
Price change
Today-0.62%lower-0.17%higher
1 year+41.3%higher+25.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Johnson & Johnson / Novartis). Who owns JNJ · Who owns NVS

Further comparisons

Learn

Questions and answers

Which is bigger, Johnson & Johnson or Novartis?

By market value, Johnson & Johnson is the larger: $675.9B against $302B for Novartis. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $54.5B for Novartis.

Which has the higher P/E ratio?

Johnson & Johnson: 42.6, against 30.5 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has more debt?

Johnson & Johnson: $47.9B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Johnson & Johnson and Novartis?

In their latest 13F filings, Tweedy, Browne team, Jeremy Grantham (co-founder), Ken Fisher, Andrew Spokes, Charles Brandes (founder), Murray Stahl, Rajiv Jain and Dodge & Cox team hold both.

Cite this page

Funkfolio, “Johnson & Johnson vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/jnj-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.